Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.

@article{Dekkers1999ComparisonOR,
  title={Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.},
  author={Cornelius PM Dekkers and Johannes A. Beker and Bjarni Thj{\'o}dleifsson and Antoni Gabryelewicz and N E Bell and Thomas J. Humphries},
  journal={Alimentary pharmacology & therapeutics},
  year={1999},
  volume={13 2},
  pages={179-86}
}
BACKGROUND Rabeprazole sodium is the newest member of a class of substituted benzimidazole molecules known as proton pump inhibitors. Other proton pump inhibitors have been shown to be effective in healing active duodenal ulcer. METHOD This randomized, double-blind, multicentre study, conducted at 25 European sites, compared the efficacy and tolerability of rabeprazole and omeprazole in patients with active duodenal ulcers. One hundred and two patients with active duodenal ulcer received… CONTINUE READING